Review

A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes

Meike Chevillotte a, Jens von Einem a, Benjamin M. Meier c, Feng-Mao Lin d, Hans A. Kestler b,c,∗, Thomas Mertens a,∗∗

a Institute of Virology, University Hospital Ulm, D-89081 Ulm, Germany
b Internal Medicine I, University Hospital Ulm, D-89081 Ulm, Germany
c Institute of Neural Information Processing, University of Ulm, D-89069 Ulm, Germany
d Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsin-Chu 300, Taiwan, ROC

A B S T R A C T

Drug resistant strains of human cytomegalovirus (HCMV) in patients at risk may increasingly develop into a problem in the clinical setting. Genotypic resistance testing is becoming the method of choice, but requires previous phenotypic characterisation of each newly found mutation. In order to facilitate the interpretation of the patient’s CMV sequence data, a web-based search tool was generated that links the sequence to a database containing all published UL97 (protein kinase) and UL54 (DNA polymerase) mutations and corresponding antiviral drug susceptibility phenotypes. It is reasonable to assume that HCMV drug resistance testing will provide relevant data for an adjustment of therapy and on prognosis of clinical outcome. HCMV drug susceptibility testing will become even more important once new drugs will be available for therapy allowing a wider choice of antiviral agents to treat HCMV disease. These topics will also play a pivotal role for optimising antiviral therapy of HCMV- and other viral diseases.

© 2009 Elsevier B.V. All rights reserved.

Contents

1. Introduction ................................................................. 319
2. Currently available systemic drugs and their resistance mechanisms ......................................................... 319
3. Antiviral drug susceptibility testing of HCMV
   3.1. Current methods for phenotypic characterisation of drug susceptibility in HCMV ........................................ 319
   3.2. Genotypic susceptibility testing ........................................ 320
   3.3. Linking genotypic and phenotypic susceptibility testing of HCMV
         3.3.1. Marker transfer analyses of resistance mutations ................................................................. 320
         3.3.2. A new search tool and database of UL97 and UL54 mutations ............................................... 321
4. Current treatment options for HCMV infection and disease ................................................................. 323
   4.1. Prophylaxis, pre-emptive and deferred therapy ..................................................................................... 323
   4.2. HCMV resistance: clinical incidence and impact ................................................................................... 323
5. Future needs ........................................................................ 324
   5.1. Clinical evaluation—correlation of assay data with clinical outcome data ............................................. 324
   5.2. Incorporation of new drugs and targets into the database ................................................................. 324
6. Conclusions ........................................................................ 324
   Acknowledgements .......................................................... 325
   References ......................................................................... 325

∗ Corresponding author at: Institute of Neural Information Processing, University of Ulm, 89069 Ulm, Germany. Tel.: +49 731 5024248; fax: +49 731 5024156.
∗∗ Corresponding author at: Institute of Virology, University Hospital Ulm, 89081 Ulm, Germany. Tel.: +49 731 500 65100; fax: +49 731 500 65102.
E-mail addresses: hans.kestler@uni-ulm.de (H.A. Kestler), thomas.mertens@uniklinik-ulm.de (T. Mertens).

0166-3542/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
doi:10.1016/j.antiviral.2009.10.004
1. Introduction

Human cytomegalovirus (HCMV) is a highly relevant opportunistic pathogen for individuals with a compromised or immature immune system, such as transplant recipients, patients with acquired immunodeficiency disease syndrome (AIDS) or congenital infected children. HCMV is the leading cause of birth defects caused by intrauterine virus infections, but unfortunately, no effective treatment is currently licensed during pregnancy. Without antiviral intervention, HCMV–associated disease represents a main cause of morbidity and mortality in solid organ transplant (SOT) and in bone marrow or hematopoietic stem cell transplant (BMT/HSCST) recipients (Boeckh et al., 2004; Boeckh and Ljungman, 2009; Sia and Patel, 2000; Sun et al., 2008). The incidence of HCMV–related complications and death in AIDS patients has declined due to the introduction of highly active antiretroviral therapy (HAART) (Kedhar and Jabs, 2007; Palella et al., 1998), but still remains a concern in patients with low CD4+ cell counts. Therefore, diagnosis and monitoring of active HCMV infection and, in many cases, long-term antiviral therapy against HCMV are life-saving for patients at risk for severe HCMV disease.

Many factors influence the success of anti–HCMV treatment, such as the underlying disease, the severity of immunosuppression, concentrations of the antiviral drugs, and finally the susceptibility of the patient’s viral strain – or viral strains – to the administered antiviral drug. Virologists have to provide clinically valid methods for fast and reproducible drug susceptibility testing in order to (i) determine viral drug resistance as reason for failure of therapy, (ii) optimise antiviral therapy, and (iii) provide a new prognostic marker.

This review recapitulates current treatment options for HCMV infection and disease, resistance mechanisms and methods for drug susceptibility testing. In this context, a new tool is presented that links HCMV genotypes to a database of published in vitro drug susceptibility phenotypes, thereby providing information for an optimisation of antiviral therapy. Furthermore, future needs are discussed, such as required clinical validation of antiviral resistance testing using the proposed interpretation system as well as the incorporation of future drugs and drug targets into the database.

2. Currently available systemic drugs and their resistance mechanisms

Three systemic drugs are currently licensed to treat HCMV infections and disease: Ganciclovir (GCV) including its prodrug Valganciclovir (ValGCV), Cidofovir (CDV) and Foscarnet (FOS). All drugs target the viral DNA polymerase, pUL54. GCV acts as nucleoside analogue and has to be initially phosphorylated by the HCMV protein kinase, pUL97 (Chiar and Chen, 1996; Michel et al., 1998; Sullivan et al., 1992). CDV does not require this initial phosphorylation step and acts as nucleotide analogue. Finally, FOS has a different mode of action by acting as pyrophosphate analogue (Chrisp and Clissold, 1991).

The two viral proteins involved in resistance mechanisms against these three drugs are pUL97 and pUL54. Defined mutations in pUL97 lead to reduced phosphorylation activities resulting in lower levels of monophosphorylated – and thus active – GCV (Baldanti et al., 2002a; Biron et al., 1986). The degree of residual pUL97 phosphorylation activity and reduced drug susceptibility is quite variable, depending on the position of the mutated amino acid (Baldanti et al., 2002a; Chou et al., 1995a, 1995b). Hence, mutations in UL97 exclusively confer resistance to GCV, and about 90% of all GCV resistances detected so far have been attributed to mutations in UL97 (Chou, 1995). Mutations in the polymerase may increase its exonuclease activity, so that the nucleoside analogues GCV and CDV are recognised and excised from the DNA chain more efficiently. Additionally, other polymerase mutations are thought to decrease affinity for antiviral compounds, a mechanism that concerns all three antivirals mentioned and thus may lead to multidrug resistance (Gilbert and Boivin, 2005a).

It has been described that the evolution of antiviral resistance occurs in a stepwise fashion (reviewed in Nijhuis et al., 2009; Müller and Kräusslich, 2009). Prior treatment, the entire virus population naturally contains only a small fraction of less drug susceptible variants. This phenomenon can be explained by a reduction of replicative fitness of those variants. When subsequent antiviral treatment does not suppress viral replication completely, e.g. due to suboptimal levels of antiviral drugs or extreme immunosuppression of the host, a selection process favouring these variants is initiated. Since they can further replicate in the presence of the antiviral drug, they are able to evolve and acquire additional mutations that enhance replicative fitness and possibly increase resistance, finally resulting in a large population of highly resistant and replication competent viruses. Concerning HCMV, this model is supported by the fact that major risk factors for HCMV drug resistance are the residual capacity of the host’s immune system to control viral replication and the overall amount and duration of viral replication (Drew, 2000). The clinical virologist has to keep these selection mechanisms in mind when monitoring viral loads in patients responding to antiviral therapy. Furthermore, the moment of antiviral drug susceptibility testing combined with the sensitivity of applied assays has to be critically evaluated.

3. Antiviral drug susceptibility testing of HCMV

3.1. Current methods for phenotypic characterisation of drug susceptibility in HCMV

Before the establishment of genotypic testing, phenotypic testing of clinical isolates was the method of choice for determining HCMV drug susceptibility and it still is in many laboratories. In theory, phenotyping should be advantageous, since drug susceptibility of the clinical isolate including all acquired mutations can directly be assessed. However, major disadvantages of phenotypic testing are the difficulties in obtaining the isolate from a patient’s sample – especially after onset of therapy – selection of a sensitive virus population during the isolation process and in general the slow replication of HCMV which delays results up to several weeks. In consequence, phenotypic testing can in most cases only be used for retrospective determination of resistance. Although the method is still used for diagnostic purposes, the main importance of phenotypic testing today relies on the characterisation of newly found mutations after marker transfer experiments in order to provide the necessary basis for genotypic resistance testing.

As recommended by the Food and Drug Administration in 2007, drug susceptibility of a viral strain to a specific antiviral agent should be expressed as the drug concentration that is effective to inhibit viral replication in vitro by 50% (EC50). Today, the gold standard for phenotypic characterisation of HCMV is still the plaque reduction assay (PRA), which measures viral spread in cell culture using different antiviral drug concentrations and counting newly formed viral plaques. However, inter–assay and especially inter–laboratory standardisation of the PRA has been shown to be very difficult (Landry et al., 2000). These difficulties can be attributed mainly to differences in cell cultures used by different laboratories. In consequence, efforts have been made to develop new assays, which allow for a better standardisation. Some are based on reporter cell lines measuring HCMV spread in cell culture reflected by luciferase activity (Gilbert and Boivin, 2005b), green fluorescent protein (GFP) (Ueno et al., 2006; Ueno and Ogawa-Goto, 2009), or enhanced green fluorescent protein (EGFP) (Luganini et al., 2008). Another approach is to use quantitative real–time PCR to detect...
the declining number of genome copies in cell culture due to different concentrations of the antiviral agent (Schnepf et al., 2009). As these assays measure a signal instead of counting plaques, they are less biased and thus allow for a better standardisation of drug susceptibility testing of clinical isolates. Other assays are based on recombinant viruses and can therefore not be applied directly for characterisation of clinical isolates, but are used for marker transfer experiments. These viruses express different reporter proteins (Marschall et al., 2000), GFP (Marschall et al., 2000), EYFP (Dal Pozzo et al., 2008) or EGFP (Chevillotte et al., 2009). The expression of reporter proteins can be quantified in a plate reader detecting chemiluminescence (Chou et al., 2005) or fluorescence (Chevillotte et al., 2009) or by flow cytometry (Dal Pozzo et al., 2008; Marschall et al., 2000) and used to calculate EC50 values. Finally, EC50 values have also been determined by a non-radioactive in vitro assay which determines viral polymerase activity by measuring the incorporation of labelled nucleotides (Ducancelle et al., 2007).

These new methods are often easier to perform and better standardised than the PRA, and are important tools to identify and characterise mutations relevant for reduced drug susceptibility. Still, all assays, including the PRA, lack clinically validated data defining which increase in the EC50 value is likely to cause clinical resistance in the patient.

3.2. Genotypic susceptibility testing

Genotypic susceptibility testing is becoming the method of choice, because reliable results can be obtained within hours (Drew, 2007). Concerning the drugs available today, the two relevant genes, UL97 and UL54, are amplified from patient material and subsequently screened for mutations. pUL97 comprises 707 amino acids (AA), and all resistance associated mutations proven by marker transfer are located between AA 460 and 607 (reviewed in Chou, 2008; Schreiber et al., 2009) (Fig. 1A). Therefore a relatively small region of approx. 600 base pairs of UL97 has to be sequenced. In addition, the five most frequently detected resistance conferring mutations – M460V, H520Q, A594V, L595L and C603W – represent about 80% of all found UL97 mutations (Schreiber et al., 2009).

In contrast, the situation for UL54 is much more complex: (i) the protein is much larger, (ii) number and diversity of mutations are higher and (iii) resistance associated mutations are located in several clusters (Fig. 1B), which all together requires sequencing of a region of over 2.5 kb. In addition, the position of the mutation in the protein seems to determine the resistance phenotype. Mutations located in the exonuclease domains tend to confer resistance against the two nucleoside analogues (Chou et al., 2003; Cihlar et al., 1998a, 1998b; Drew et al., 2006; Ducancelle et al., 2005; Lurain et al., 1992; Marfori et al., 2007; Scott et al., 2007), whereas mutations between AA 588 and 715 have been described in association with FOS resistance (Baldanti et al., 1996; Cihlar et al., 1998a; Ducancelle et al., 2005; Mousavi-Jazi et al., 2001; Springer et al., 2005). Finally, mutations between AA 756 and 982 are linked to resistance against any of the three drugs – to one drug alone or combinations (Baldanti et al., 1996; Chou and Marousek, 2008; Chou et al., 1997, 2003; Cihlar et al., 1998a; Drew et al., 2006; Mousavi-Jazi et al., 2001; Scott et al., 2007; Springer et al., 2005; Tchesnokov et al., 2006; Weinberg et al., 2003) (Fig. 1B).

One important advantage of genotypic resistance testing is the detection of mutant virus subpopulations. Up to now, the sensitivity of PCR followed by conventional (Sanger) sequencing methods is sufficient to detect subpopulations that exceed 10% of the whole virus population (Schreiber et al., 2009). However, this might not be sensitive enough to detect subpopulations in the early phase of therapy. A novel approach to overcome this problem and to increase sensitivity could be the use of pyrosequencing techniques (Ronaghi et al., 1998), which reliably allows for the detection and quantification of mixed UL97 populations starting from 6%, and for specific mutations even starting from 2 to 3% (Bernd Ehlers, personal communication).

An additional matter of genotypic resistance testing may be that HCMV populations may differ in their composition within one single patient in different compartments (Eckle et al., 2000; Erice et al., 1997; Michel et al., 2003). For example, this has been described by analysing the proportion of a genotypically resistant subpopulation in different isolates from various compartments, obtained on the same day from a heart transplant patient (Michel et al., 2003). The report showed that the percentage of resistant virus was 80% in the isolated virus population obtained from a throat wash, 50% from urine, and no resistant virus could be detected in the isolate obtained from leucocytes. These results highlight the importance not only to investigate the composition of the viral population but also to consider the relevant compartments.

Finally, the major challenge of genotypic resistance testing is to link its results to corresponding resistance phenotypes. Genotypic susceptibility testing definitely requires prior phenotypic characterisation of the respective mutations – and combinations – in order to distinguish between "baseline" – clinically irrelevant – and resistance conferring mutations. In fact, a number of potentially resistance associated mutations found in clinical isolates have been shown not to be responsible for an increase in EC50 values in marker transfer experiments.

3.3. Linking genotypic and phenotypic susceptibility testing of HCMV

3.3.1. Marker transfer analyses of resistance mutations

In marker transfer experiments, mutations suspected to confer resistance are introduced into a well defined, drug-sensitive viral background and then tested phenotypically. Thus, these experiments are able to provide the link between genotype and drug susceptibility phenotype. Different protocols have been published for the generation of such recombinant HCMV strains for drug susceptibility testing.

Early protocols were based on either cotransfection of HCMV DNA or transfection of HCMV infected cells with linear DNA containing the mutated sequence. After recombination of the DNA in the transfected cell, recombinant viruses bearing the desired mutation could be reconstituted and then plaque purified in order to avoid wild-type virus contamination (Baldanti et al., 1996; Bourgeois et al., 1997; Chou et al., 2000; Cihlar et al., 1998a; Faizi Khan et al., 1998; Lurain et al., 1992; Mousavi-Jazi et al., 2001; Sullivan et al., 1992). These approaches do not produce a clonal virus population, as wild-type virus contaminations can never be completely suppressed, influencing the results of drug susceptibility testing. Other methods use a drug-sensitive parental HCMV strain that bears unique restriction sites in the target gene. The parental DNA is digested with a restriction enzyme and cotransfected with a plasmid containing the mutation(s) of interest in the respective gene. Recombination between overlapping sequences in the plasmid and the digested parental DNA in cotransfected cells results in viable recombinant virus harbouring the desired mutation(s) (Chou, 2008; Chou and Marousek, 2008; Chou et al., 2003, 2005; Drew et al., 2006; Iwasenko et al., 2009; Marfori et al., 2007; Scott et al., 2007; Springer et al., 2005; Weinberg et al., 2003). This method highly increases the selective pressure for the formation of recombinant virus compared to wild-type virus, but plaque purification is still necessary. The problem of wild-type virus contamination has been first circumvented using an in vitro assay, where only the mutated enzymes, and not viruses, are generated and tested for drug susceptibility (Ducancelle et al., 2005, 2007). More recently, bacterial artificial chromosome (BAC) technology
Fig. 1. (A) HCMV UL97 (kinase) and (B) UL54 (polymerase) regions, mutations associated with drug resistance and corresponding drug resistance phenotypes. Shown are only marker transfer proven mutations. N=N-terminus; C=C-terminus; pol=polymerase; Exo=exonuclease domain; GCVr=Ganciclovir resistance; CDVr=Cidofovir resistance; FOSr=Foscarnet resistance.

has been applied to generate clonal recombinant viruses for marker transfer experiments. Since all progeny viruses go back to BAC DNA from one single bacterial colony, clonal virus populations are obtained. Several protocols have been published for the generation of recombinant BACs for HCMV marker transfer purposes, based on a flip recombinase (Martin et al., 2006), RED recombinase (Chou, 2009), or RED-GAM recombinase system (Chevillotte et al., 2009). Only the latter two are markerless mutagenesis methods, meaning that they leave no trace of the recombination procedure in the BAC sequence (Tischer et al., 2006; Warming et al., 2005). BAC mutagenesis is efficient and relatively fast, and is now becoming the method of choice for the characterisation of the many still uncharacterised mutations. The number of needed marker transfers has further increased since we know that combinations of mutations in UL97 and UL54 on the one hand sometimes have a synergistic effect on the decrease of drug susceptibility (Ducancelle et al., 2007; Mousavi-Jazi et al., 2001; Scott et al., 2007), but can on the other hand also partially compensate for each other (Iijichi et al., 2002). Therefore, the influence of combinations is difficult to predict and has to be analysed in additional marker transfer experiments.

3.3.2. A new search tool and database of UL97 and UL54 mutations

More than 60 publications on HCMV resistance mutations are now available, reporting over 50 UL97 and over 150 UL54 mutations. In order to allow a fast interpretation of sequence data from genotypic susceptibility testing, we have generated a web-based search tool where a patient's CMV UL97 or UL54 sequence can be uploaded and will be subsequently compared to the wild-type sequence of the drug-sensitive HCMV strain TB40-BAC4 (Chevillotte et al., 2009; Sinzger et al., 2008). Detected mutations will be linked to a regularly updated database that contains all published UL97 and UL54 mutations and the corresponding in vitro phenotypes, thus providing important parameters for the evaluation of mutations. If a mutation is found that is not yet known or presented in the database, it can be reported (via email) and will be integrated into the database. The procedure for the HCMV mutation identification is as follows: We use BLASTX (version: NCBI BLAST 2.2.18) (Altschul et al., 1990, 1997) to align UL54/UL97 wild-type protein sequence and a given UL54/UL97 nucleotide sequence (see Fig. 2). Possible amino acid mutations of the given HCMV strand can then be identified. According to the mutation locations and mutated amino acids, the system compares the mutations with HCMV mutation database and reports which type of mutations and associated literature are present in the given HCMV sequence (see http://www.informatik.uni-ulm.de/ni/mitarbeiter/HKestler/hcmv).

The results provided for a previously published mutation contain (i) its qualitative drug susceptibility phenotype (as stated by the respective authors), (ii) its quantitative drug susceptibility phenotype (the ratio of EC50 values compared to wild type), (iii) its viral replicative fitness, a parameter that might also influence clinical outcome (Emery and Griffiths, 2000), (iv) the respective publication, with a link to pubmed, and (v) the assay used in the cited publication. In addition, the location of the mutation is indicated in a linear scheme of the respective protein containing all resistance associated entries represented in the database. If a sequence has been submitted, its position is shown in the scheme, so that it can be easily controlled whether all relevant regions are covered by the sequencing reaction (Fig. 3).

The success of all “genotype to phenotype” approaches in revealing relevant data highly depends on the quality of the phenotypic data. Therefore, knowledge of the methods used for generating the phenotypic data is very important regarding the assessment of reliability. For example, reliability is much higher when the data is based on clonal marker transfer experiments combined with the use of a reporter system for a phenotypic readout than when it is entirely based on sequence data from a patient with therapy failure.
Fig. 2. Flowchart of the sequence analysis.

Fig. 3. Visualisation of the web-based search tool available at http://www.informatik.uni-ulm.de/ni/mitarbeiter/HKestler/hcmv.
4. Current treatment options for HCMV infection and disease

There are basically two options to help the patient’s organism in terminating an active systemic HCMV infection: either by improving the immunologic situation, or by the administration of antiviral drugs. Enhancement of the patient’s immune status can be achieved, e.g., by reduction of an immunosuppressive therapy after SOT (Egli et al., 2007) or by effective treatment of an HIV infection which is indispensable in order to further improve the basis for an antiviral therapy using anti-T-cell antibodies in renal transplant recipients (von Müller et al., 2006).

Another important yet controversial point is the definition of resistance. Different publications use different definitions, e.g. 2-fold increases in EC50 values (Chou et al., 2003) or absolute EC50 values that have to be exceeded (Drew et al., 2006; Smith et al., 1997). Others have defined mutations detected in a specimen from an individual patient as resistance conferring based on correlation with clinical failure of therapy (Oshima et al., 2008). However, those definitions are arbitrary and lack proper clinical validation. We decided to enter information on the qualitative susceptibility phenotype into the database “as stated by the respective authors” without adding an additional arbitrary definition. In the future, clinical studies have to be performed in order to assess the relevance of specific mutations for clinical outcome and the need of adjustment of therapy.

Up to now, the knowledge about drug resistance of HCMV is mainly based on phenotypic data from cell culture experiments. These data are now easily accessible via our search tool. Clinical evaluation of the data will be a major challenge in the future, which is indispensable in order to further improve the basis for an optimisation of antiviral therapy against HCMV.

4.2. HCMV resistance: clinical incidence and impact

“Clinical resistance” and “viral resistance” are often used synonymously, although they represent two different entities. The term “clinical resistance” means no response of clinical parameters to the antiviral drug (Reusser et al., 1996). Yet, clinical resistance may have other reasons than the presence of a resistant HCMV, such as the underlying disease, the type and severity of immunosuppression, and concentrations of the antiviral drugs. In contrast, the term “viral resistance” stands for the presence of a drug resistant viral strain, and is commonly divided into phenotypic and genotypic resistance, depending on the method of testing.

The incidence of viral drug resistance of HCMV strongly varies in the numerous studies analysing this problem, depending on different parameters such as (i) the group of patients (pre-existing conditions), (ii) the medication profile, (iii) the time of testing, (iv) the method of testing (e.g. geno- or phenotypic), (v) whether the
study was performed retrospectively or prospectively and finally (vi) the definition of “resistance”. All mentioned parameters make it difficult to directly compare the data of these respective studies.

The emergence of drug resistant HCMV strains was first described in AIDS patients. Up to 27% of AIDS patients carried a phenotypically resistant HCMV strain after 12 months of anti-HCMV therapy (Jabs et al., 1998a, 1998b). The baseline phenotypic resistance – before treatment – was below 3%. The percentage increased with the duration of therapy and the occurrence of resistant HCMV strains was generally associated with unfavourable clinical outcome in those patients. In another study, the authors found that after 12 months of anti-HCMV therapy 12.8% of patients carried genotypically resistant strains (Boivin et al., 2001), indicating the impact of the method of testing mentioned above on the incidence of viral drug resistance. Since introduction of HAART, the frequency of HCMV disease in AIDS patients has sharply declined, due to an improvement of the immunologic situation of the patients (Kedhar and Jabs, 2007; Palella et al., 1998). Nevertheless, HCMV disease together with antiviral resistance remains a problem in patients with failure of HAART therapy (Baldanti et al., 2002b).

For SOT patients, the clinical impact seems to be lower than for AIDS patients. A large retrospective study including 240 SOT patients found genotypic resistance in 2.1% of all patients at a median of 10 months post-transplantation (Limaye et al., 2000). Resistance was only detected in previously seronegative patients who had obtained a seropositive graft (D+/R−), and the percentage of viral resistance was 7%. Among these patients, resistance was most frequently found after kidney-pancreas transplantation with an incidence of 21%. Overall, resistant HCMV strains were responsible for 20% of HCMV diseases during the first year post-transplantation. However, it is possible that these retrospective studies tend to overestimate the prevalence of HCMV resistance because of a selection bias. This is supported by two prospective studies with SOT patients, where a lower incidence of genotypic resistance (between 0% (treatment with ValGCV) and 6.1% (oral GCV)) was found (Boivin et al., 2004, 2005). Interestingly, in the latter two studies, resistant strains did not seem to be necessarily associated with adverse clinical outcome, as some patients harbouring resistant strains remained totally asymptomatic.

In a setting of pronounced immunosuppression, the maximum frequency of HCMV resistance in adult HSCT patients has been reported to be as high as 8% (Boechk et al., 2003, 2004; Boechk and Ljungman, 2009). Apart from these data, only case reports seem to be available for the HSCT/BMT patients setting (Erice et al., 1998; Julien et al., 2002; Springer et al., 2005), reporting poor clinical outcome associated with the detection of resistant HCMV strains. The situation is slightly different in the pediatric setting, where resistant strains seem to emerge very rapidly, starting from weeks after exposure to the drug (Eckle et al., 2000, 2002; Wolf et al., 1998).

In conclusion, prospective, standardised studies have to be performed in order to assess the occurrence of resistant HCMV strains as well as their relevance for clinical outcome. To address this point, the generation of a database where results from such clinical studies can be uploaded and evaluated seems to be an excellent tool.

5. Future needs

5.1. Clinical evaluation—correlation of assay data with clinical outcome data

Our new web-based search tool together with the database as it is today is derived from published associations between HCMV genotypes and corresponding cell culture resistance phenotypes, which is currently the best information available. However, medical validation of such a tool – and of resistance testing in general – is a crucial point for its successful use in the clinical setting. It is therefore necessary to perform studies linking the susceptibility data to standardised studies, monitoring viral and clinical data longitudinally. With this knowledge, it is essential to define procedures for therapeutic recommendations and prognosis of therapeutic response. Databases of rules have already been established for other viruses, e.g. the Stanford University HIV drug resistance database (http://hivdb.stanford.edu/), Geno’s geno2pheno tool (http://www.geno2pheno.org), the HIV Grade tool (http://www.hiv-grade.de) or the HIV French resistance tool (http://www.hivfrenchresistance.org), and some of these have already undergone clinical evaluation.

Regarding HCMV, only few case reports are currently available to answer questions about therapeutic recommendation and clinical prognosis. One example is the UL97 mutation C592G, originating from an AIDS patient (Chou et al., 1997). This mutation has been shown to confer a moderate, 2.3- to 2.9-fold, increase of EC50 values for GCV in marker transfer analyses (Chou et al., 2005; Iwasenko et al., 2009). C592G was detected after therapy with oral GCV and antiviral therapy was continued. Consequently, highly resistant virus populations, bearing other UL97 and additional UL54 mutations, were selected, which led to therapeutic failure and caused the death of the patient (Chou et al., 1997). Another case report described the effect of the UL97 mutation N597D, found in a heart transplant patient after ValGCV treatment. This mutation confers only low-grade reduction of susceptibility to GCV (EC50 ratio 1.4, confirmed by marker transfer analyses). Continuation of therapy with ValGCV lead to clearance of CMV from the blood, and the patient had no further episodes of CMV-related symptoms (Iwasenko et al., 2009), indicating that the virus population bearing this mutation can be controlled by applying optimum doses of GCV. Obviously, prospective studies have to be performed in order to define a clear cut-off for EC50 values indicating the need of switching therapy to another antiviral drug.

5.2. Incorporation of new drugs and targets into the database

As already mentioned, all available anti-HCMV drugs share the same target, pUL54, so that one single mutation may lead to multidrug resistance. Therefore, it is imperative to find new drugs against HCMV having different targets. Several compounds are currently under investigation, targeting viral entry, replication, or virion assembly and egress (reviewed in Andrei et al., 2008, 2009). The most promising among these compounds is Maribavir (MBV), although its future is unclear because of unfavourable results in clinical phase III trials (Mark Ullan, symposium at the 12th International CMV/Betaherpesvirus Workshop, Boston, MA, 2009). MBV acts as an inhibitor of UL97 (Biron et al., 2002) and so far, no cross-resistance to GCV, CDV and FOS has been reported. Up to now, mutations conferring a reduced susceptibility have been found only in vitro (Chou and Marousek, 2008; Chou et al., 2007). These have been shown to map in the viral genes UL97 and UL27 (Chou et al., 2004; Komazin et al., 2003). The example of MBV demonstrates that the complexity of HCMV resistance testing will increase not only because of additional drugs, but also because of additional targets bearing new resistance associated mutations. Once licensed, these new drugs and their respective targets will be incorporated into the database, thereby increasing its importance, as information from the database will allow more systematic choices of medications based on the resistance profiles.

6. Conclusions

In recent years, the treatment of HCMV disease and clinical outcome has been enormously improved by monitoring active systemic infections and the introduction of HCMV antiviral therapy.
Nevertheless, the situation concerning HCMV treatment is complex and still not satisfying. Taken the current knowledge into account, it can be assumed that many factors contribute to the overall drug susceptibility phenotype of a patient’s virus population. Among those are the underlying disease, the degree of immunosuppression, the clinical sample, the type and position of mutations in UL97 and UL54, the viral replicative fitness, and finally – depending on the replicative fitness – the dynamics of a resistant virus population.

The questions of the treating clinician are clearly defined: (i) who has to be treated, (ii) when to start, (iii) which antiviral drug to use, (iv) when to augment the dosage or switch the drug due to virological susceptibility findings?

Since phenotypical testing of isolated viruses is not practicable in the clinics, genotyping is the method of choice because results can be obtained reliably within hours. Still, all individual mutations in the genes relevant for resistance have to be characterised phylogenotypically, including combinations of these mutations. Our new web-based search tool and database will be a major improvement for the fast evaluation of sequence data regarding their susceptibility phenotype. Finally, reduced drug susceptibility – virological resistance – has to be correlated with therapy failure – clinical resistance – and patient’s outcome in prospective clinical studies.

Acknowledgements

We would like to thank Johann M Kraus and Bernd Ehlers for the information on detection of HCMV subpopulations by pyrosequencing. Meike Chevillotte is participant in the International Graduate School in Molecular Medicine Ulm, funded by the Excellence Initiative of the German federal and state governments. University Hospital Ulm and the Robert-Koch-Institut, Berlin (Netzwerk für Infektionen bei man federal and state governments. University Hospital Ulm and the Robert-Koch-Institut, Berlin (Netzwerk für Infektionen bei

References


late mofetil on the incidence and severity of primary cytomegalovirus infections
recombination for versatile high-efficiency markerless DNA manipulation in
Novel real-time monitoring system for human cytomegalovirus-infected cells in
vitro that uses a green fluorescent protein-PML-expressing cell line. Antimicrob.
Agents Chemother. 50, 2806–2813.
Ueno, T., Ogawa-Goto, K., 2009. Use of a GFP-PML-expressing cell line as a biosensor
Vigano, M., Dengler, T., Mattei, M.F., Poncelet, A., Vanhaecke, J., Vermees, E., Kleinloog,
infection with everolimus versus mycophenolate mofetil in de novo
Dis.
von Müller, L., Schliep, M., Hämpl, W., Schmid, T., Abendroth, D., Mertens,
T., 2006. Severe graft rejection, increased immunosuppression, and active CMV
Warming, S., Costantino, N., Court, D., Jenkins, N.A., Copeland, N.G., 2005. Simple and
highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33,
e36.
Weinberg, A., Jabs, D.A., Chou, S.W., Martin, B.K., Lurain, N.S., Forman, M.S.,
of patients with acquired immunodeficiency syndrome and cytomegalovirus
emergence of ganciclovir-resistant human cytomegalovirus strains in children